Meet with us at VIVE 2024!

Examining the Impact of Connected Devices on GLP-1 Therapy

Empowering Digital Health Programs to Make Swift Clinical Decisions

In a March 2024 survey, Withings Health Solutions asked their database of device users about their experience with GLP-1 treatments and the biomarkers they’ve been monitoring throughout their health journey, garnering responses from 2352 participants.

Part 3: Supporting Safe and Sustainable Weight Loss With GLP-1s – Managing weight after medication

Weight gain is likely when patients stop taking a GLP-1 therapy. A 2022 study found patients who took the GLP-1 semaglutide had regained two thirds of their prior weight and had similar cardiometabolic changes a year after stopping the medication. Prescribers at doctor’s offices and virtual weight loss programs should track patients throughout their journey and when they stop taking GLP-1s. This monitoring of daily progress provides long-term oversight of weight loss goals and maintenance.

The Science Behind Body Pro 2 – Body Composition

Body Pro 2 utilizes multifrequency BIA technology for the evaluation of patient body composition to offer accurate and repeatable measurements to care teams. This enables healthcare providers to receive daily measurements from their patients, facilitating the long-term tracking of their progress and thus allowing for in-depth follow up with personalized advice.